“We’re cheaper than your current compounder.” Your rep sends a vial price. Finance asks whether that number is one month or two. Shipping and processing show up on a different screen. By Friday your team is rebuilding the same spreadsheet you hoped to retire.
That is not a failure to negotiate. It is the wrong question. Google answers “are compounding pharmacies cheaper?” for patients comparing clinic programs to retail pharmacy. Clinic ops need a different frame: landed cost per patient-period across 503A partners before anyone quotes a member.
Who this is for
This article is for clinic ops leads, pharmacy coordinators, and founder-led telehealth finance owners who evaluate 503A compounders and set cash-pay member pricing.
You are not the audience if you are a patient hunting the lowest GLP-1 monthly price or asking whether compounding is safer than brand medication. This is coordinator-side commercial ops content. It is not medical advice and does not cover clinical candidacy or dosing.
The wrong question vs the clinic question
Patient-facing SERP content asks whether compounding beats retail pharmacy or brand GLP-1 on sticker price. That is a membership marketing debate.
Your buying question is narrower:
| Patient SERP question | Clinic ops question |
|---|---|
| Is compounding cheaper than my local CVS? | Which 503A partner has lower landed COGS at our protocol? |
| Should I skip the clinic and order direct? | Can we quote members from numbers we trust before checkout? |
| Are compounded GLP-1 programs 50% off brand? | Does this partner win after supply duration and fees align? |
| Which compounder is most trusted? | Which partner’s invoice matches the catalog on our top SKUs? |
If you are comparing partners for Friday refills, you are not in the patient column. You are building a landed-cost worksheet.
The scene ops teams describe on vendor calls
On a recent discovery call with a national telehealth ops team, the same pricing friction showed up we hear from scaled weight-loss and hormone brands:
- “Are these base prices?”
- “Shipping fee… processing fee…”
- “How much would it be a month, two months, worth of medication?”
- “We need to compare currently the pricing from our different pharmacy partners.”
They were not asking whether compounding beats brand Ozempic for a shopper on Reddit. They needed credible landed math so coordinators could quote subscribers and leadership could pick partners without a three-day spreadsheet rebuild every quarter.
We need apples-to-apples landed cost per patient, for the same strength and supply duration, before we commit.
That is what “cheaper” should mean on your side of the desk.
When a compounding quote looks cheaper (and when it is not)
A 503A partner can legitimately cost less per patient-month. It can also look cheaper because the quote is incomplete.
Supply duration hides the real month
A $149 vial that covers 14 days is not cheaper than a $189 vial that covers 28 days until you normalize to cost per patient-period. Sales decks love two-week starter vials because the number is smaller. Finance loses when nobody divides by approximate days of supply.
See month vs two-month compound supply pricing for the full normalization workflow.
Base price is not landed cost
Reps quote medication only. Processing hits at checkout. Shipping changes by state. A facilitation fee may be bundled inside the drug line or added on top. The partner that wins on base price often loses on estimated landed cost.
Platform markup masquerades as drug cost
Some clinic portals bake 40 to 80 percent intermediary markup into the vial price. You think you are comparing compounders when you are comparing middlemen. Pass-through catalogs separate drug cost from disclosed facilitation so COGS is visible before you quote.
Per-order fees punish high-volume clinics
Two partners with the same vial price diverge when one charges $15 processing per order and $29 flat shipping on every refill while another spreads fees differently across line items. High-volume telehealth brands feel that on Monday batch checkout, not on the first demo cart.
The clinic comparison table (not a patient savings chart)
Build every partner column on these rows before you call anyone “cheaper”:
| Row | Partner A | Partner B | Partner C |
|---|---|---|---|
| Medication + strength | Semaglutide 2.5 mg/mL | Semaglutide 2.5 mg/mL | Semaglutide 2.5 mg/mL |
| Supply duration (approx. days) | 28 days | 28 days | 14 days |
| Base medication price | $165 | $149 | $129 |
| Facilitation / platform fee | Bundled in drug | $8 disclosed | Bundled in drug |
| Processing | $12 | $0 | $12 |
| Shipping | $29 flat | $19 | $29 flat |
| Estimated landed cost | $206 | $176 | $170 |
| Landed cost per 28 days | $206 | $176 | $340 |
Partner C looked cheapest on vial sticker price. Normalized to the same 28-day patient-period, Partner C is the most expensive column.
That is the worksheet behind how to compare 503A pharmacy pricing apples to apples.
What to compare instead of “cheaper”
Replace the yes/no question with this checklist:
- Same strength and concentration on every partner row
- Same approximate days of supply, or explicit per-month normalization
- Every fee through delivery: facilitation, processing, shipping
- Landed cost per patient-period ranked, not vial price alone
- Catalog price matches checkout on your top five SKUs
- Member quote built from COGS, not from a competitor’s patient-facing ad
For semaglutide-heavy programs, define landed cost per vial at each titration step before membership tiers move.
For multi-partner evaluations, use the full prescription price comparison workflow across 503A partners so PDFs from three compounders land on one row format.
Five mistakes when clinics ask “is this compounder cheaper?”
1. Treating patient savings content as vendor selection research.
Articles about compounded GLP-1 vs brand are for shoppers. Your job is COGS math, not debate club.
2. Comparing one partner’s month to another’s two months.
Different supply duration is a different SKU. Normalize first.
3. Signing on base price before shipping and processing appear.
If the demo cannot show landed cost on one screen, expect invoice surprises.
4. Ignoring platform markup inside the drug line.
A lower vial from a portal may include hidden margin a pass-through catalog would show separately.
5. Quoting members before the chart is done.
Wrong membership pricing is harder to unwind than a slow vendor decision. Landed cost first, member quote second.
Questions to ask before you call a partner “cheaper”
Use these on demos and reference calls:
- Is this price base medication only or landed cost?
- How many days of supply does this vial represent at our standard protocol?
- Where do shipping and processing show up: catalog, cart, or invoice only?
- Is medication pass-through or does platform markup sit inside the vial line?
- Can you match the same strength and supply duration as our current partner on one export?
- Does checkout total match the number your rep quoted on our typical order size?
If answers shift between catalog browse and checkout, “cheaper” was a teaser.
Where Fizy Health fits (honest framing)
Fizy Health is built for clinics that already use 503A compounders and need one ordering layer with economics you can see before you commit. We are not a compounding pharmacy and we will not tell you compounding is always cheaper than every alternative.
Pass-through pricing shows resolved per-vial 503A cost in the medication catalog and on every cart line. Clinic checkout separates drug cost from disclosed facilitation before card authorization, so your comparison chart matches what coordinators see on screen.
That supports the outcome ops buyers name on calls: landed cost per patient-period on the same strength and supply duration before you quote. Telehealth-specific context lives on the telehealth ops page. Platform fee structure is on the pricing page.
We will tell you straight if pass-through economics do not beat your current all-in cost. Do not switch for a blog post.
Bottom line
Compounding pharmacies are not automatically cheaper for clinics. The useful comparison is landed cost per patient-period across 503A partners at the same strength and supply duration, with every fee row visible.
Stop asking whether compounding beats retail pharmacy in the abstract. Build the worksheet, rank landed cost, then quote members from COGS you trust.